BCLI

Companies
NASDAQ
Brainstorm Cell Therapeutics Inc.
Health Care
Price Chart
Overview

About BCLI

Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Market Cap
$28.8M
Volume
44.7K
Avg. Volume
40.7K
P/E Ratio
-0.4878049
Dividend Yield
0.00%
Employees
26.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
0.76
Moderate Correlation
Volatility
High (1.00)
Relative to market

Macro Factor Sensitivities

Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
High Sensitivity
Liquidity
High Sensitivity
Commodity Prices
High Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for BCLI.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, BCLI shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$28.8M
Volume44.7K
P/E Ratio-0.49
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 31, 2025
Related Securities

PortfolioPilot Analysis

Get AI-powered insights on how BCLI fits into your investment strategy and portfolio diversification.

Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025